Medical Developments International Limited · ASX:MVP
Medical Developments International — Jefferies 2017 Global Healthcare Conference
51 slides from Medical Developments International's conference presentation, Jun 8, 2017
Slide 1: ASX Announcement: Presentation at Jefferies 2017 Global Healthcare Conference
8 June 2017 For personal use only ASX ANNOUNCEMENT Presentation at Jefferies 2017 Global Healthcare Conference – June 9, New York Medical Developments International Limited (ASX: MVP) is pleased to announce that it is presenting at the ‘2017 Jefferies Global Healthcare Conference’ in New York from 6
Slide 2: About Penthrox and Medical Developments International
About Penthrox For personal use only Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with e
Slide 3: Medical Developments International – Jefferies Healthcare Conference
For personal use only Medical Developments International USA Jefferies Healthcare Conference June 2017 | New York, USA
Slide 4: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, For personal use only ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discu
Slide 5: Vision
Vision For personal use only Medical Developments International (MVP) is a leading Emergency Medicine Company. Our aim is to: 1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader in these markets glo
Slide 6: The Business
The Business For personal use only MVP is delivering two world class “company making” business opportunities. The risk profile of these opportunities is relatively low and well understood. Penthrox: Penthrox has the potential to be the market leader in acute pain markets around the world. Penthrox i
Slide 7: Introducing Penthrox
For personal use only Introducing Penthrox® 5
Slide 8: A world class opportunity
Penthrox® A world class opportunity For personal use only Penthrox® • Market Leader for trauma pain • Opiate sparing, fast acting inhalational analgesic 1 • 85% of patients reach clinical analgesia within 6-10 breaths • Is a solution to a significant unmet clinical need • Demonstrated safety and eff
Slide 9: A world class opportunity
Penthrox® A world class opportunity For personal use only Penthrox® • Sold in 17 countries around the world including Australia, UK, France, Belgium, Ireland , South Africa, Singapore, New Zealand, UAE, Qatar and elsewhere. • Major distribution deals signed in Europe and elsewhere since 2015. • $18.
Slide 10: Planned launches
Penthrox® Planned launches For personal use only MVP expect to achieve Regulatory approval to sell Penthrox in approximately 37 additional countries in the next 18 months including:- Czech Republic Italy Germany Sweden Switzerland Jordan Poland Iraq Slovakia Canada Macedonia Austria Albania South Ko
Slide 11: History and planned launches
Penthrox® History and planned launches 2010 For personal use only Pre 2000 2015 2020 2021 - 2022 Planned 2019- 2020 Launch: Malaysia Planned 2017 & 2018 Thailand Launch: Philippians Planned Launch: Brazil 2016 Canada Indonesia Columbia 2014 Launched: Germany Chile Launched: Irela
Slide 12: Penthrox clinical program for USA
Penthrox® Penthrox® clinical program for USA For personal use only 2017 2018 2019 2020 FDA Approval IND Toxicology: Repeat dose and dose ranging - 2 by 28 Day Repeat Dose Healthy Volunteer Trial studies - General validation and Additional Phase III to support assay studies to support existing Phase
Slide 13: Penthrox clinical program for USA
Penthrox® Penthrox® clinical program for USA For personal use only MVP had it’s second meeting with the FDA in May 2017 The pre-clinical program was agreed The IND enabling study was agreed MVP expect to open its IND during FY2018 MVP is working towards Penthrox being approved for sale in the USA du
Slide 14: Clinical application
Penthrox® Clinical application For personal use only Painful procedures Painful procedures • Burn injuries • Cutaneous excisions Cosmetic Dentistry Surgery • Liquid nitrogen removals of • Breaks, fractures and skin-cancers, warts, etc. dislocations Military Consulting • Invasive angiographies Rooms
Slide 15: Benefits to medical professionals
Penthrox® Benefits to medical professionals For personal use only Rapid onset Minimal waiting time before a painful procedure can be performed (3 minutes) and of action rapid pain relief when a patient is treated for acute pain, trauma, and minor surgical procedures. Inhaled Medical professionals ca
Slide 16: Benefits over Opiates
Penthrox® Benefits over Opiates For personal use only The benefits of using Penthrox® over Morphine include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox can be used on children, Morphine often cannot. • Penthrox is not a narcotic, nor is i
Slide 17: Benefits over Nitrous Oxide
Penthrox® Benefits over Nitrous Oxide For personal use only The benefits of using Penthrox® over Nitrous Oxide include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox is self-administered and easy to use. • Penthrox is compact and can be used
Slide 18: Provides rapid pain relief
Penthrox® Provides rapid pain relief For personal use only Average pain reduction from point of adminstration1-2 Time (minutes) 0 0 5 10 15 20 30 -5 Morphine Adjusted change from baseline (mm) Fentanyl Visual Analogue Scale (VAS) -10 Penthrox® Pain Intensity Score -15 -20 -25 -30 -35 -40 1 COFFEY, F
Slide 19: Can reduce patient waiting times to analgesia
Penthrox® Can reduce patient waiting times to analgesia For personal use only USA wait times to analgesia2 80 70 Time (minutes) 60 Average time 50 to analgesia 40 30 minute 30 target 20 Penthrox® assists by being: 10 Self administered 0 Easy to use Virginia Iowa Kansas Nevada Alabama Mississippi
Slide 20: Can reduce resources used in pain management
Penthrox® Can reduce resources used in pain management For personal use only 1TODD, Knox, 2010. Chronic Or Recurrent Pain In The Emergency Department: National Telephone Survey Of Patient Experience; Western Journal of Emergency Medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3027428/ 2 PALME
Slide 21: Can reduce overcrowding in EDs
Penthrox® Can reduce overcrowding in EDs For personal use only Penthrox® has the ability to improve an ED’s medical care as it can: Reduce the time to analgesia Leads to: Increase patient satisfaction levels Treatment of patients outside Reduce the costs to hospitals designated zones Admin
Slide 22: Can reduce the cost of analgesia
Penthrox® Can reduce the cost of analgesia Average costs of an IV Opioid treatment Average costs of a Penthrox® treatment* For personal use only Drug Administration, Staffing & Patient $25 Total Cost: Monitoring, $117 Total Cost: Drug Administration, $1,298 $563* $15.75 Adverse Events Costs, $113 St
Slide 23: History of Penthrox
History of Penthrox® Clinical studies & publications to present For personal use only Pre-2005 Studies 2005 2010 2017 Obstetrics Burns Pharmacology Colonoscopy Dentistry Prehospital ED Obstetrics Burns Dental Burns Paediatrics ED Pivotal Bone Marrow Analgesia Post-Op Phase III Occupa
Slide 24: History of Penthrox
History of Penthrox® Clinical studies & publications to present For personal use only patients have been studied in more than 75 clinical trials over 30 years Penthrox is used synonymously with methoxyflurane 22
Slide 25: History of Penthrox
History of Penthrox® Clinical studies & publications to present For personal use only 235,861 patients 3% 3% Pharmacology 5% 8% 3% Paediatrics 5% 3% Toxicology Prehospital 8% Safety Emergency Department 3% Wound Care/ Burns Dentistry 22% Military 11% Colonoscopy Radiology Urology 3% Bone Marrow Biop
Slide 26: Future of Penthrox: Clinical development program
Future of Penthrox® Clinical development program For personal use only Additional clinical trials and studies are planned for FY17 (and beyond) which will broaden the indications for use of Penthrox®. Our longer term ambition is to extend the use of Penthrox® into: • Acute Pain / Minor Surgical Proc
Slide 27: Future of Penthrox: Acute trauma pain potential sales
Future of Penthrox® Potential global sales for Acute Trauma pain $2 billion+ For personal use only Peak sales in UK estimated to be Peak sales in Canada could be $50 $72 million per annum* million per annum* Peak sales in Europe estimated to be $250 million per annum* Peak sales in Asia could be $50
Slide 28: Future of Penthrox: Breakthrough pain potential sales
Future of Penthrox® Potential global sales for Breakthrough pain $6 billion+ For personal use only Peak sales in USA could Peak sales in Europe could be $2 be $2 billion per billion per annum* annum* Peak sales in Asia could be $1.5 billion per annum* Peak sales in Latin America could be $500 millio
Slide 29: Future of Penthrox: Minor surgical procedures potential sales
Future of Penthrox® Potential global sales for selected Minor Surgical Procedures $2.3 billion+ For personal use only Peak sales in USA Peak sales in Europe estimated to be $814 million per annum* could be $1.3billion per annum* Peak sales in Asia could be $147 million per annum* Peak sales in Latin
Slide 30: Future of Penthrox: Home use potential sales
Future of Penthrox® Potential global sales for Home Use $3 billion+ For personal use only Peak sales in USA could Peak sales in Europe could be $1 billion per annum* be $900 million per annum* Peak sales in Asia could be $620 million per annum* Peak sales in Latin America estimated to be $230 millio
Slide 31: Intellectual Property
Penthrox® Intellectual Property For personal use only MVP is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. MVP has filed and is managing the following patents and trademarks: • 6 Penthrox Inhaler patents; • 1 manufacturing patent; a
Slide 32: Manufacturing
Penthrox® Manufacturing For personal use only MVP has invested millions of dollars developing new manufacturing technology, techniques and methods. MVP has: 1. Intellectual property. 2. Global production capacity. 3. Lowest cost to manufacture. 4. Significant competitive advantage. 30
Slide 33: Outlook
Penthrox® Outlook For personal use only MVP’s ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 18 months we expect to: 1. Obtain approval to sell Penthrox in more than 30 countries throughout Europe
Slide 34: Introducing Respiratory Devices
For personal use only Introducing Respiratory Devices 32
Slide 35: MVP Medical Respiratory division
MVP Medical Respiratory division For personal use only MVP has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication. In 2011 MVP launched a new range of products using MVP’s Cross Valve TechnologyTM, a patented system of drug
Slide 36: MVP Medical Respiratory division
MVP Medical Respiratory division For personal use only MVP offers a range of devices that can be used to help patients manage and take control of their asthma and COPD. • Space Chamber PlusTM anti-static spacer range • Space Chamber PlusTM spacer • Space ChamberTM Autoclavable • Compact Spacer Chamb
Slide 37: Respiratory Devices: Existing distribution network
Respiratory Devices Existing distribution network For personal use only Netherlands Switzerland Austria Germany UK Belgium Canada Greece Italy Cyprus USA Spain Korea Portugal Hong Kong Singapore Malaysia UAE KSA New Zealand Australia 35
Slide 38: Respiratory Division: Future
Respiratory Division Future For personal use only MVP respiratory products: • now sell in 20 countries; • are ranged and/or available in 10,000 pharmacies across the USA; • have achieved full reimbursement from healthcare funds in the USA; • are Australia’s leading brand with an estimated market sha
Slide 39: Respiratory Division: Future
Respiratory Division Future For personal use only MVP is investing heavily in developing new and innovative products • Anti static spacers • Anti static mask – (1st of its kind) • Collapsible spacer • Economical spacer • Additional patentable devices and technology Two new products will be launched
Slide 40: USA respiratory devices update
Sales & Marketing USA respiratory devices update For personal use only USA Asthma update There are circa 67,000 pharmacies in the USA. There are circa 18.4 million adults suffering from Asthma1 There are circa 6.2 million children suffering from Asthma1 There are circa 3,651 deaths each year in the
Slide 41: Key Pharmacy accounts update
Sales & Marketing USA respiratory devices update For personal use only Key Pharmacy accounts update Walmart – April 2017 • 4,624 US stores • Ranging confirmed & orders placed with McKesson • 2 SKUs in all stores, 2 remaining SKUs with limited distribution K-Mart – April 2017 • 1,000 US stores • Rang
Slide 42: Key Pharmacy Buying Groups update
Sales & Marketing USA respiratory devices update For personal use only Key Pharmacy Buying Groups update Independent Pharmacy Co-op – March 2017 • 3,000 independent US stores • Ranging confirmed and first orders received Price Choppers – April 2017 • 88 US stores • Ranging confirmed and first orders
Slide 43: Respiratory Devices: Intellectual Property
Respiratory Devices Intellectual Property For personal use only MVP is protecting its future by generating intellectual property from its new range of respiratory devices. MVP has filed a number of global patents. MVP has filed international Trade Marks and Registered Designs in more than 20 countri
Slide 44: Respiratory Devices: Outlook
Respiratory Devices Outlook For personal use only MVP’s ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 20 countries. Over the next 12 months we expect to: 1. Obtain additional partnership deals in the USA an
Slide 45: Introducing MVP Corporate
For personal use only Introducing MVP Corporate 43
Slide 46: Financial Summary
Financial Summary For personal use only MVP has been profitable every year since listing on the ASX in 2003 and: • has generated a positive cash flow every year; • pays tax and has paid fully franked dividends; • has received almost $20 million in upfronts and milestones in the last 18 months; • has
Slide 47: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3yr) Current Stock Price 0.000 (0.00%) 4.71 1 Jun, 12:02pm Day High 4.710 Day Low 4.690 Open 4.710 Prev. Close 4.710 Avg. Volume 35,826 52 Wk. High 6.440 (24 Jun 2016) 52 Wk. Low 4.120 (6 Dec 2016) Mkt. Cap 276.59 (Mil)
Slide 48: MVP Corporate Overview
MVP Corporate Overview For personal use only David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing Director A Medical Co
Slide 49: MVP Global Strategy
MVP Global Strategy New and revised For personal use only materials and process (lowest cost producer and New significant IP) Business Partners Product innovation (world’s best manufacturing processes and delivery devices resulting in significant IP) Clinical trials (Commercial clinical studies to s
Slide 50: Contact Details
Contact Details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com 48
Slide 51: Medical Developments International
For personal use only Medical Developments International
Medical Developments International — Jefferies 2017 Global Healthcare Conference on 6ix